Work with Us
Initiated Phase 1 clinical trial in 10 patients to assess both safety and clinical efficacy. First two sites, Mayo Clinic and Univ of Michigan, have been activated in July and August of 2023 to recruit patients.
FDA’s approval of HRGN’s first IND is an extremely important milestone for HRGN as it will transition Biostage into a clinical stage company
Recent Press
About Us
Regenerations Ahead
HRGN is a clinical-stage biotechnology company that uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases.
About Us
Regenerations Ahead
HRGN is a clinical-stage biotechnology company that uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases.
Subscription to Newsletter
Sign up for trending updates on Medical Industry.